β-Adrenergic Receptor Signaling and Heart Failure: From Bench to Bedside.

Despite improvements in management and therapeutic approach in the last decades, heart failure is still associated with high mortality rates. The sustained enhancement in the sympathetic nervous system tone, observed in patients with heart failure, causes alteration in β-adrenergic receptor signaling and function. This latter phenomenon is the result of several heart failure-related molecular abnormalities involving adrenergic receptors, G-protein-coupled receptor kinases, and β-arrestins. This article summarizes novel encouraging preclinical strategies to reactivate β-adrenergic receptor signaling in heart failure, including pharmacologic and gene therapy approaches, and attempts to translate acquired notions into the clinical setting.

[1]  H. Rockman,et al.  β-Arrestin–dependent activation of Ca2+/calmodulin kinase II after β1–adrenergic receptor stimulation , 2010, The Journal of cell biology.

[2]  R. Lefkowitz,et al.  Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  K. Swedberg,et al.  [Expert Consensus document on beta-adrenergic receptor blockers]. , 2004, Revista espanola de cardiologia.

[4]  S. Emani,et al.  In Vivo Ventricular Gene Delivery of a &bgr;-Adrenergic Receptor Kinase Inhibitor to the Failing Heart Reverses Cardiac Dysfunction , 2001, Circulation.

[5]  R. Lefkowitz,et al.  Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. , 1998, Circulation.

[6]  H. Rockman,et al.  Β-arrestin: a signaling molecule and potential therapeutic target for heart failure. , 2011, Journal of molecular and cellular cardiology.

[7]  R. Lefkowitz,et al.  Recent developments in biased agonism. , 2014, Current opinion in cell biology.

[8]  R. Lefkowitz,et al.  Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. , 1995, Science.

[9]  W. Koch,et al.  Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: Signaling and Actions in the Cardiovascular System , 2017, Front. Pharmacol..

[10]  D. Leosco,et al.  GRK2 as a novel gene therapy target in heart failure. , 2011, Journal of molecular and cellular cardiology.

[11]  D. Leosco,et al.  Negative Impact of &bgr;-Arrestin-1 on Post-Myocardial Infarction Heart Failure via Cardiac and Adrenal-Dependent Neurohormonal Mechanisms , 2014, Hypertension.

[12]  Robert J. Lefkowitz,et al.  Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A , 1997, Nature.

[13]  F. Rengo,et al.  Lymphocyte G-protein-coupled receptor kinase-2 is upregulated in patients with Alzheimer's disease , 2007, Neuroscience Letters.

[14]  S. Houser,et al.  GRK5-Mediated Exacerbation of Pathological Cardiac Hypertrophy Involves Facilitation of Nuclear NFAT Activity , 2014, Circulation research.

[15]  E. Lakatta,et al.  Transgenic manipulation of beta-adrenergic receptor kinase modifies cardiac myocyte contraction to norepinephrine. , 1997, The American journal of physiology.

[16]  R. Lefkowitz,et al.  Beta-arrestins and cell signaling. , 2007, Annual review of physiology.

[17]  J. Violin,et al.  β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection , 2007 .

[18]  J. Floras.  The "unsympathetic" nervous system of heart failure. , 2002, Circulation.

[19]  Antonio S. Tutor,et al.  Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease. , 2006, Cardiovascular research.

[20]  P. Filardi,et al.  β-adrenergic receptors and G protein-coupled receptor kinase-2 in Alzheimer's disease: a new paradigm for prognosis and therapy? , 2013, Journal of Alzheimer's disease : JAD.

[21]  N. Weintraub,et al.  A carvedilol-responsive microRNA, miR-125b-5p protects the heart from acute myocardial infarction by repressing pro-apoptotic bak1 and klf13 in cardiomyocytes. , 2018, Journal of molecular and cellular cardiology.

[22]  Olivier Lichtarge,et al.  β-Arrestin-dependent, G Protein-independent ERK1/2 Activation by the β2 Adrenergic Receptor* , 2006, Journal of Biological Chemistry.

[23]  N. Dzimiri.  Receptor crosstalk. Implications for cardiovascular function, disease and therapy. , 2002, European journal of biochemistry.

[24]  Michel Bouvier,et al.  Development and Characterization of Pepducins as Gs-biased Allosteric Agonists*♦ , 2014, The Journal of Biological Chemistry.

[25]  D. Liccardo,et al.  GRK2 as a therapeutic target for heart failure , 2018, Expert opinion on therapeutic targets.

[26]  M. Caron,et al.  Differential Affinities of Visual Arrestin, βArrestin1, and βArrestin2 for G Protein-coupled Receptors Delineate Two Major Classes of Receptors* , 2000, The Journal of Biological Chemistry.

[27]  J. Cheung,et al.  Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility. , 2012, ACS chemical biology.

[28]  W. Koch,et al.  GRK2 inhibition in heart failure: something old, something new. , 2012, Current pharmaceutical design.

[29]  J. Spertus,et al.  A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure , 2008, Nature Medicine.

[30]  B. Kobilka,et al.  Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. Lefkowitz,et al.  β-Arrestin 2: A Receptor-Regulated MAPK Scaffold for the Activation of JNK3 , 2000 .

[32]  R. Xiao,et al.  &bgr;-arrestin 2 mediates cardiac ischemia-reperfusion injury via inhibiting GPCR-independent cell survival signalling , 2017, Cardiovascular research.

[33]  N. Dzimiri,et al.  Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. , 2004, European journal of pharmacology.

[34]  M. Caron,et al.  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. , 1999, Science.

[35]  Robert J. Lefkowitz,et al.  Transduction of Receptor Signals by ß-Arrestins , 2005, Science.

[36]  W. Koch,et al.  Determining the Absolute Requirement of G Protein–Coupled Receptor Kinase 5 for Pathological Cardiac Hypertrophy: Short Communication , 2012, Circulation research.

[37]  G. Dorn,et al.  G Protein–Coupled Receptor Kinase 2 Activity Impairs Cardiac Glucose Uptake and Promotes Insulin Resistance After Myocardial Ischemia , 2011, Circulation.

[38]  N. Weintraub,et al.  Carvedilol-responsive microRNAs, miR-199a-3p and -214 protect cardiomyocytes from simulated ischemia-reperfusion injury. , 2016, American journal of physiology. Heart and circulatory physiology.

[39]  J. Tesmer,et al.  Molecular Mechanism of Selectivity among G Protein-Coupled Receptor Kinase 2 Inhibitors , 2011, Molecular Pharmacology.

[40]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[41]  B. Trimarco,et al.  L41Q polymorphism of the G protein coupled receptor kinase 5 is associated with left ventricular apical ballooning syndrome , 2010, European journal of heart failure.

[42]  W. Koch,et al.  Future G protein-coupled receptor targets for treatment of heart failure , 2009, Current treatment options in cardiovascular medicine.

[43]  Robert J. Lefkowitz,et al.  Seven-transmembrane-spanning receptors and heart function , 2002, Nature.

[44]  W. Koch,et al.  Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction , 2015, Science Translational Medicine.

[45]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[46]  E. Braunwald,et al.  New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1. , 1986, The New England journal of medicine.

[47]  E. Braunwald,et al.  New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. , 1986, The New England journal of medicine.

[48]  W. Koch,et al.  The expanding GRK interactome: Implications in cardiovascular disease and potential for therapeutic development. , 2016, Pharmacological research.

[49]  S. Jamieson,et al.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. , 1986, Circulation research.

[50]  G. Dorn,et al.  Adrenergic signaling polymorphisms and their impact on cardiovascular disease. , 2010, Physiological reviews.

[51]  D. Parikh,et al.  Insulin induces IRS2-dependent and GRK2-mediated β2AR internalization to attenuate βAR signaling in cardiomyocytes. , 2015, Cellular signalling.

[52]  H. Kurose,et al.  β-Adrenergic Receptor and Insulin Resistance in the Heart , 2017, Biomolecules & therapeutics.

[53]  G. Andersen,et al.  Myocardial distribution and regulation of GRK and beta-arrestin isoforms in congestive heart failure in rats. , 2001, American journal of physiology. Heart and circulatory physiology.

[54]  H. Rindt,et al.  Cardiac-specific Overexpression of a 1BAR Regulates AR Activity Via Molecular Crosstalk , 1998 .

[55]  A. Lochner,et al.  Signal transduction in myocardial ischaemia and reperfusion , 1996, Molecular and Cellular Biochemistry.

[56]  J L Benovic,et al.  Regulation of G protein-coupled receptor kinases. , 2000, Trends in cardiovascular medicine.

[57]  Ja Johnson,et al.  Cardiovascular Pharmacogenomics of Adrenergic Receptor Signaling: Clinical Implications and Future Directions , 2011, Clinical pharmacology and therapeutics.

[58]  J L Benovic,et al.  Phosphorylation/dephosphorylation of the beta-adrenergic receptor regulates its functional coupling to adenylate cyclase and subcellular distribution. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M. Börjesson,et al.  A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. , 2000, European heart journal.

[60]  T. Palmer,et al.  &bgr;1-Adrenergic Receptor and Sphingosine-1-Phosphate Receptor 1 (S1PR1) Reciprocal Downregulation Influences Cardiac Hypertrophic Response and Progression to Heart Failure: Protective Role of S1PR1 Cardiac Gene Therapy , 2013, Circulation.

[61]  R. Lefkowitz,et al.  Preservation of myocardial β-adrenergic receptor signaling delays the development of heart failure after myocardial infarction , 2000 .

[62]  D C Harrison,et al.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.

[63]  Christopher M. Tan,et al.  Membrane trafficking of G protein-coupled receptors. , 2004, Annual review of pharmacology and toxicology.

[64]  A. Lymperopoulos.  Ischemic emergency?: endothelial cells have their own "adrenaline shot" at hand. , 2012, Hypertension.

[65]  W. Koch,et al.  Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. , 2007, Trends in molecular medicine.

[66]  S. Marullo,et al.  The Myocardium-protective Gly-49 Variant of the β1-Adrenergic Receptor Exhibits Constitutive Activity and Increased Desensitization and Down-regulation* , 2002, The Journal of Biological Chemistry.

[67]  D. Leosco,et al.  Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. , 2005, European heart journal.

[68]  P. Filardi,et al.  Prognostic Value of Lymphocyte G Protein-Coupled Receptor Kinase-2 Protein Levels in Patients With Heart Failure. , 2016, Circulation research.

[69]  J. Chun,et al.  S1P1 Receptor Localization Confers Selectivity for Gi-mediated cAMP and Contractile Responses* , 2008, Journal of Biological Chemistry.

[70]  J. Cheung,et al.  β-arrestin–biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction , 2016, Proceedings of the National Academy of Sciences.

[71]  A. Sandilands,et al.  Greater inotropic and cyclic AMP responses evoked by noradrenaline through Arg389 β1‐adrenoceptors versus Gly389 β1‐adrenoceptors in isolated human atrial myocardium , 2003, British journal of pharmacology.

[72]  D. Bers.  Calcium cycling and signaling in cardiac myocytes. , 2008, Annual review of physiology.

[73]  G. Dorn,et al.  Low- and high-level transgenic expression of β2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice , 1999 .

[74]  C. Ribas,et al.  Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. , 2003, Cellular signalling.

[75]  Eric Reiter,et al.  GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling , 2006, Trends in Endocrinology & Metabolism.

[76]  P. Molinoff,et al.  International Union of Pharmacology nomenclature of adrenoceptors. , 1994, Pharmacological reviews.

[77]  D. Schwartz,et al.  Activation of protein kinase C by angiotensin II decreases beta 1-adrenergic receptor responsiveness in the rat heart. , 1997, Journal of cardiovascular pharmacology.

[78]  D. Lu,et al.  Angiotensin receptors and norepinephrine neuromodulation: implications of functional coupling , 1997, Regulatory Peptides.

[79]  T. Eschenhagen.  β-adrenergic signaling in heart failure—adapt or die , 2008, Nature Medicine.

[80]  D. Leosco,et al.  β1-Blockade Prevents Post-Ischemic Myocardial Decompensation Via β3AR-Dependent Protective Sphingosine-1 Phosphate Signaling. , 2017, Journal of the American College of Cardiology.

[81]  W. Koch,et al.  Adrenergic Nervous System in Heart Failure: Pathophysiology and Therapy , 2013, Circulation research.

[82]  W. Koch,et al.  &bgr;-Arrestin2 Improves Post–Myocardial Infarction Heart Failure via Sarco(endo)plasmic Reticulum Ca2+-ATPase–Dependent Positive Inotropy in Cardiomyocytes , 2017, Hypertension.

[83]  A. Tucker,et al.  Phospholemman-Phosphorylation Mediates the β-Adrenergic Effects on Na/K Pump Function in Cardiac Myocytes , 2005, Circulation research.

[84]  M. Nishida,et al.  Clathrin Required for Phosphorylation and Internalization of β2-Adrenergic Receptor by G Protein-coupled Receptor Kinase 2 (GRK2)* , 2006, Journal of Biological Chemistry.

[85]  A. Briasoulis,et al.  Meta-analysis of the effects of carvedilol versus metoprolol on all-cause mortality and hospitalizations in patients with heart failure. , 2015, The American journal of cardiology.

[86]  Martin J. Lohse,et al.  What Is the Role of &bgr;-Adrenergic Signaling in Heart Failure? , 2003, Circulation research.

[87]  J. Balligand,et al.  The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. , 1998, The Journal of clinical investigation.

[88]  J. Ross,et al.  Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[89]  Catherine Communal,et al.  Opposing Effects of β1- and β2-Adrenergic Receptors on Cardiac Myocyte Apoptosis Role of a Pertussis Toxin–Sensitive G Protein , 1999 .

[90]  S. Ferguson,et al.  Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. , 2001, Pharmacological reviews.

[91]  H. Kurose,et al.  Multiple functions of G protein-coupled receptor kinases , 2014, Journal of molecular signaling.

[92]  E. Lakatta,et al.  The β2-Adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gi-Dependent coupling to phosphatidylinositol 3'-kinase , 2000 .

[93]  O. Brodde.  Beta-adrenoceptors in cardiac disease. , 1993, Pharmacology & therapeutics.

[94]  M. Böhm,et al.  Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. , 1993, Circulation.

[95]  P. Singh,et al.  Structural and Functional Analysis of G Protein–Coupled Receptor Kinase Inhibition by Paroxetine and a Rationally Designed Analog , 2014, Molecular Pharmacology.

[96]  S. Milano,et al.  Regulation of receptor trafficking by GRKs and arrestins. , 2007, Annual review of physiology.

[97]  A. Lymperopoulos,et al.  β1-adrenoceptor Arg389Gly polymorphism confers differential β-arrestin-binding tropism in cardiac myocytes. , 2016, Pharmacogenomics.